Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
160.25(c) 157.69(c) 159.2(c) 160.11(c) 161.3(c) Last
4 101 646 6 686 443 6 901 589 4 580 894 6 893 194 Volume
-0.42% -1.60% +0.96% +0.57% +0.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 93 970 M - -
Net income 2021 22 809 M - -
Net cash position 2021 2 466 M - -
P/E ratio 2021 18,7x
Yield 2021 2,58%
Sales 2022 97 371 M - -
Net income 2022 23 507 M - -
Net cash position 2022 14 817 M - -
P/E ratio 2022 17,3x
Yield 2022 2,75%
Capitalization 425 B 425 B -
EV / Sales 2021 4,49x
EV / Sales 2022 4,21x
Nbr of Employees 134 500
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
10/19Earnings Release
More about the company
Ratings of Johnson & Johnson
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOHNSON & JOHNSON
10/15S&P 500 Posts 1.8% Weekly Gain, Strongest Since July, Amid Positive Start to Q3 Results..
MT
10/15JOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Us..
PR
10/15STREET COLOR : Global Calendar For Week Ending October 22
MT
10/15JOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Receives FDA Advisory Panel Recommendati..
MT
10/15FDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
10/15JOHNSON & JOHNSON : COVID-19 Vaccine Wins FDA Advisory Panel's Backing as Booster for Adul..
MT
10/15JOHNSON & JOHNSON : Earns a Spot on Fortune's 2021 Change the World List
PU
10/15JOHNSON & JOHNSON : Janssen Gets Positive Opinion on Lung Cancer Treatment From European M..
MT
10/15FDA PANEL BACKS JOHNSON & JOHNSON CO : Bloomberg
MT
10/15CORONAVIRUS : Peace Corps Helps Launch Vaccination Campaign in Commune of Mantasoa The cam..
AQ
10/15GLOBAL MARKETS LIVE : Macy's, Boeing, RioTinto, Virgin Galactic, Nestlé...
10/15JOHNSON & JOHNSON : OPSYNVI« (macitentan and tadalafil) Becomes the First and Only Health ..
PU
10/15PRO BANKRUPTCY BRIEFING : J&J Unit Files Bankruptcy Over Talc Claims; Purdue Appeals to Be..
DJ
10/15JOHNSON & JOHNSON : OPSYNVI« (macitentan and tadalafil) Becomes the First and Only Health ..
PU
10/15PROTECTING COMMON-INTEREST PRIVILEGE : Guidance From Recent Decisions
AQ
More news
News in other languages on JOHNSON & JOHNSON
10/15Le S&P 500 affiche une hausse hebdomadaire de 1,8 %, la plus forte depuis juillet, dans..
10/15MÄRKTE USA/Wall Street geht mit deutlichen Aufschlägen ins Wochenende
10/15La piqûre de rappel du vaccin COVID-19 de Johnson & Johnson reçoit la recommandation du..
10/15USA : un comité d'experts recommande une dose supplémentaire au vaccin anti-
10/15USA : FDA-Gremium empfiehlt auch Corona-Booster mit Johnson & Johnson
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 161,30 $
Average target price 185,83 $
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283